These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 19652769)

  • 21. Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids.
    Seely KA; Lapoint J; Moran JH; Fattore L
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Dec; 39(2):234-43. PubMed ID: 22561602
    [TBL] [Abstract][Full Text] [Related]  

  • 22. On the addictive power of gabapentinoids: a mini-review.
    Bonnet U; Richter EL; Isbruch K; Scherbaum N
    Psychiatr Danub; 2018 Jun; 30(2):142-149. PubMed ID: 29930223
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ["Addiction" to phenelzine - case report].
    Antosik-Wójcińska AZ; Bzinkowska D; Chojnacka M; Swiecicki Ł; Torbiński J
    Psychiatr Pol; 2013; 47(1):127-34. PubMed ID: 23888750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alprazolam dependence in seven patients.
    Juergens SM; Morse RM
    Am J Psychiatry; 1988 May; 145(5):625-7. PubMed ID: 3258735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term cannabis abuse and early-onset cannabis use increase the severity of cocaine withdrawal during detoxification and rehospitalization rates due to cocaine dependence.
    Viola TW; Tractenberg SG; Wearick-Silva LE; Rosa CS; Pezzi JC; Grassi-Oliveira R
    Drug Alcohol Depend; 2014 Nov; 144():153-9. PubMed ID: 25262527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of acute detoxification of the herbal blend 'Spice Gold' on dopamine D2/3 receptor availability: a [18F]fallypride PET study.
    Rominger A; Cumming P; Xiong G; Koller G; Förster S; Zwergal A; Karamatskos E; Bartenstein P; La Fougère C; Pogarell O
    Eur Neuropsychopharmacol; 2013 Nov; 23(11):1606-10. PubMed ID: 23452563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of synthetic cannabinoids on the duration of opioid-related withdrawal and craving among patients of addiction clinics in Kazakhstan: A prospective case-control study.
    Prilutskaya M; Bersani FS; Corazza O; Molchanov S
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28631421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Substance use disorders: Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) and International Classification of Diseases, tenth edition (ICD-10).
    Hasin D; Hatzenbuehler ML; Keyes K; Ogburn E
    Addiction; 2006 Sep; 101 Suppl 1():59-75. PubMed ID: 16930162
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors.
    Nielsen M; Hansen EH; Gøtzsche PC
    Addiction; 2012 May; 107(5):900-8. PubMed ID: 21992148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New Drugs of Abuse and Withdrawal Syndromes.
    Andrabi S; Greene S; Moukaddam N; Li B
    Emerg Med Clin North Am; 2015 Nov; 33(4):779-95. PubMed ID: 26493523
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Schizophrenia and amphetamine dependence. A case report].
    Dervaux A; Krebs MO; Laqueille X
    Encephale; 2005; 31(2):247-50. PubMed ID: 15959451
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pharmacological properties and dependence liabilities of synthetic cannabinoids].
    Funada M
    Nihon Arukoru Yakubutsu Igakkai Zasshi; 2010 Jun; 45(3):167-74. PubMed ID: 20681249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An independent assessment of MEDWatch reporting for abuse/dependence and withdrawal from Ultram (tramadol hydrochloride).
    Woody GE; Senay EC; Geller A; Adams EH; Inciardi JA; Schnoll S; Muñoz A; Cicero TJ
    Drug Alcohol Depend; 2003 Nov; 72(2):163-8. PubMed ID: 14636971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Drug addiction and withdrawal].
    Tacke U; Kuoppasalmi K; Airaksinen M
    Duodecim; 1998; 114(10):1003-17. PubMed ID: 11524775
    [No Abstract]   [Full Text] [Related]  

  • 35. Clinical implications for four drugs of the DSM-IV distinction between substance dependence with and without a physiological component.
    Schuckit MA; Daeppen JB; Danko GP; Tripp ML; Smith TL; Li TK; Hesselbrock VM; Bucholz KK
    Am J Psychiatry; 1999 Jan; 156(1):41-9. PubMed ID: 9892296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mixed consumption of cannabis and "Spice".
    Dziadosz M; Klintschar M; Teske J
    Forensic Sci Int; 2014 Feb; 235():e1-2. PubMed ID: 24389330
    [No Abstract]   [Full Text] [Related]  

  • 37. Cannabis withdrawal in chronic, frequent cannabis smokers during sustained abstinence within a closed residential environment.
    Lee D; Schroeder JR; Karschner EL; Goodwin RS; Hirvonen J; Gorelick DA; Huestis MA
    Am J Addict; 2014; 23(3):234-42. PubMed ID: 24724880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Synthetic cannabinoids--the new "legal high" drugs].
    Berkovitz R; Arieli M; Marom E
    Harefuah; 2011 Dec; 150(12):884-7, 937. PubMed ID: 22352277
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kratom (Mitragyna speciosa) dependence, withdrawal symptoms and craving in regular users.
    Singh D; Müller CP; Vicknasingam BK
    Drug Alcohol Depend; 2014 Jun; 139():132-7. PubMed ID: 24698080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The synthetic cannabinoid withdrawal syndrome.
    Nacca N; Vatti D; Sullivan R; Sud P; Su M; Marraffa J
    J Addict Med; 2013; 7(4):296-8. PubMed ID: 23609214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.